Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

415 questions · 442 findings · 58 reviews

No studies found 70 · 15.8%GRADE not reported 19 · 4.3%Very low 99 · 22.4%Low 137 · 31%Moderate 86 · 19.5%High 31 · 7%

Standard treatment plus systemic corticosteroids vs usual care

Preservation of visual acuity · patients age 10 years and older with periorbital or orbital cellulitis

It is very uncertain whether standard treatment plus systemic corticosteroids changes preservation of visual acuity compared with standard treatment alone (very low certainty).

1 finding from 1 review

Standard treatment plus systemic corticosteroids vs usual care

Severity of pain on day 3 · patients age 10 years and older with periorbital or orbital cellulitis

It is very uncertain whether standard treatment plus systemic corticosteroids changes severity of pain on day 3 compared with standard treatment alone (very low certainty).

1 finding from 1 review

Standard treatment plus systemic corticosteroids vs usual care

Duration of time requiring intravenous antibiotics · patients age 10 years and older with periorbital or orbital cellulitis

It is very uncertain whether standard treatment plus systemic corticosteroids changes duration of time requiring intravenous antibiotics compared with standard treatment alone (very low certainty).

1 finding from 1 review

Standard treatment plus systemic corticosteroids vs usual care

Surgical intervention · patients age 10 years and older with periorbital or orbital cellulitis

It is very uncertain whether standard treatment plus systemic corticosteroids changes need for surgical intervention compared with standard treatment alone (very low certainty).

1 finding from 1 review

Standard treatment plus systemic corticosteroids vs usual care

Adverse effects: exposure keratopathy · patients age 10 years and older with periorbital or orbital cellulitis

It is very uncertain whether standard treatment plus systemic corticosteroids changes adverse effects: exposure keratopathy compared with standard treatment alone (very low certainty).

1 finding from 1 review

Betamethasone vs usual care

Respiratory distress syndrome · women undergoing planned elective caesarean section at 37 weeks' gestation and beyond for singleton pregnancy

Effect of antenatal corticosteroids (betamethasone) showed no clear difference in respiratory distress syndrome (RDS) compared with usual care prior to planned caesarean at term on maternal and… (low certainty).

1 finding from 1 review

Betamethasone vs usual care

Transient tachypnoea of the neonate (TTN) · women undergoing planned elective caesarean section at 37 weeks' gestation and beyond for singleton pregnancy

Effect of antenatal corticosteroids (betamethasone) showed no clear difference in transient tachypnoea of the neonate (TTN) compared with usual care prior to planned caesarean at term on maternal and… (low certainty).

1 finding from 1 review

Betamethasone vs usual care

Admission to neonatal special care (all levels) for respiratory morbidity · women undergoing planned elective caesarean section at 37 weeks' gestation and beyond for singleton pregnancy

Effect of antenatal corticosteroids (betamethasone) probably leads to lower admission to neonatal special care (all levels) for respiratory… compared with usual care prior to planned caesarean at term on maternal and… (moderate certainty).

1 finding from 1 review

Betamethasone vs usual care

Need for mechanical ventilation · women undergoing planned elective caesarean section at 37 weeks' gestation and beyond for singleton pregnancy

It is very uncertain whether effect of antenatal corticosteroids (betamethasone) changes need for mechanical ventilation compared with usual care prior to planned caesarean at term on maternal and… (very low certainty).

1 finding from 1 review

Systemic corticosteroids vs placebo or control

Mortality Mortality at latest · preterm infants with chronic lung disease

Systemic corticosteroids (dexamethasone or hydrocortisone) leads to lower mortality at latest reported age compared with control (placebo or nothing) (high certainty).

1 finding from 1 review

Systemic corticosteroids vs placebo or control

Bronchopulmonary dysplasia/chronic lung disease · preterm infants with chronic lung disease

Systemic corticosteroids (dexamethasone or hydrocortisone) probably leads to lower BPD at 36 weeks' PMA compared with control (placebo or nothing) (moderate certainty).

1 finding from 1 review

Systemic corticosteroids vs placebo or control

Death or bronchopulmonary dysplasia at 36 weeks PMA · preterm infants with chronic lung disease

Systemic corticosteroids (dexamethasone or hydrocortisone) probably leads to lower mortality or BPD at 36 weeks' PMA compared with control (placebo or nothing) (moderate certainty).

1 finding from 1 review

Systemic corticosteroids vs placebo or control

Cerebral palsy · preterm infants with chronic lung disease

Systemic corticosteroids (dexamethasone or hydrocortisone) showed no clear difference in cerebral palsy ‐ at latest reported age compared with control (placebo or nothing) (high certainty).

1 finding from 1 review

Systemic corticosteroids vs placebo or control

Death or cerebral palsy · preterm infants with chronic lung disease

Systemic corticosteroids (dexamethasone or hydrocortisone) showed no clear difference in mortality or cerebral palsy ‐ at latest reported age compared with control (placebo or nothing) (high certainty).

1 finding from 1 review

Summary of findings table ‐ Corticosteroids plus standard care vs placebo or usual care

All‐cause mortality up to 30 days · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19

Summary of findings table ‐ Corticosteroids plus standard care probably leads to lower all‐cause mortality up to 30 days compared with standard care (plus/minus placebo) (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Corticosteroids plus standard care vs placebo or usual care

All‐cause mortality up to 120 days · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19

It is very uncertain whether summary of findings table ‐ Corticosteroids plus standard care changes all‐cause mortality up to 120 days compared with standard care (plus/minus placebo) (very low certainty).

1 finding from 1 review